INLCUDED GENE THERAPY DRUGS

Embarc Benefit Protection

EVERNORTH HEALTH SERVICES

FDA Approved	Drug Name	Indication	Drug Description
2024	BEQVEZ ™	Hemophilia B	For the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes
2024	LENMELDY ™	Metachromatic Leukodystrophy	For the treatment of a rare disease that affects the brains and nervous systems of children in their late infantile and early juvenile years
2024	LYFGENIA ™	Sickle Cell Disease	For the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso occlusive crises (VOCs)
2024	CASGEVY ™	Sickle Cell Disease	For the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events (VOEs)
		Beta-thalassemia	Used for a blood disorder known as beta thalassemia in patients who cannot make enough beta-globin and require regular blood transfusions
2023	ROCTAVIAN ™	Hemophilia A	A gene therapy from BioMarin for the treatment of adults with severe hemophilia A, with factor VIII activity less than 1 IU/dL, who are without pre-existing antibodies to adeno-associated virus serotype 5 (detected by an FDA-approved test.

THERAPY CLASSES

ONCOLOGY · CARDIOVASVULAR · HEMATOLOGY · RHEUMATOLOGY · TRANSPLANT · METABOLIC DISORDERS

DIABETES · OPHTHALMOLOGY · IMMUNOLOGY · DERMATOLOGY · NEUROLOGY · GENETIC DISORDERS

Last updated: August. 2024

2022	HEMGENIX®	Hemophilia B	For the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes
2022	SKYSONA®	Adrenoleukodystrophy	To slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD)
2022	ZYNTEGLO®	Beta-thalassemia	Used for a blood disorder known as beta thalassemia in patients who cannot make enough beta-globin and require regular blood transfusions
2019	ZOLGENSMA®	Spinal Muscular Atrophy	A gene therapy for children under 2 years old with spinal muscular atrophy
2017	LUXTURNA®	Retinal Dystrophy	The first FDA-approved prescription gene therapy for people with inherited retinal disease

THERAPY CLASSES

ONCOLOGY | CARDIOVASVULAR | HEMATOLOGY | RHEUMATOLOGY | TRANSPLANT | METABOLIC DISORDERS

DIABETES | OPHTHALMOLOGY | IMMUNOLOGY | DERMATOLOGY | NEUROLOGY | GENETIC DISORDERS

Last updated: August. 2024